MEETING A CRITICAL CHALLENGE
Average life expectancy has doubled since the early 1900’s. It is anticipated that more than 90 million American’s will be over 65 years of age by 2050. The number of Americans 100 years of age and older will grow from several hundred now to 2 million in the next 50 years.
This extraordinary achievement toward greater longevity has been accompanied by dramatic increases in the incidence of age-related neurological disorders, including Alzheimer’s disease (AD), Dementia, Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS).
A major challenge ahead is to discover new therapeutics and interventions that promote slower aging and delay the onset of age-related neurodegenerative disorders.
Without urgent action, the enormous burden of dementia and cognitive decline will continue to grow in the decades ahead.
The mission of the Coit Center for Longevity and Neurotherapeutics is to foster new discoveries and therapeutics that promote longevity and healthspan.
Ongoing research include efforts to:
- understand the causes and mechanisms underlying aging, resilience, neurodegeneration in Alzheimers, Parkinson and ALS
- develop new biomarkers for monitoring healthy aging
- identify new cellular processes to serve as targets for therapeutic intervention
- develop new drugs that modulate aging and neurodegeneration at their most fundamental level
- conduct clinical trials for interventions in longevity, healthspan, and decreased neurocongnitive decline
The Longevity Center will develop and test new targets, biomarkers, and therapeutics to slow aging, promote healthspan, and halt or reverse neurodegenerative disease pathology, clinical onset and progression.